『LATAM MedTech Insights』のカバーアート

LATAM MedTech Insights

LATAM MedTech Insights

著者： Ran Chen
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.Copyright 2026 Ran Chen 生物科学 科学 経済学
エピソード
  • Colombia's UDI Mandate: Pure Global on a New MedTech Compliance Trap

    Colombia's UDI Mandate: Pure Global on a New MedTech Compliance Trap
    2026/05/07
    This episode of LATAM MedTech Insights dives into a sudden and critical regulatory update from Colombia's INVIMA. Last week's clarification on Unique Device Identification (UDI) for Class IIa devices has created an immediate compliance challenge for manufacturers, requiring a new level of data management and specific submission protocols that have caught many off guard. We break down what the new guidance entails, the technical hurdles it presents, and the broader implications for MedTech companies operating in, or planning to enter, the Colombian market. We explore why this move is more than a simple labeling change and represents a significant step-up in local enforcement of global standards. A leading US-based orthopedic company, which packages multiple devices into single surgical kits, is now facing potential import blockades. Their global UDI strategy did not account for INVIMA's new demand for individual Device Identifier linking for every single Class IIa component within a kit. This case study reveals the hidden complexities and the urgent need to overhaul their data management systems to meet Colombia’s unique requirements. --- **Key Takeaways:** 1. What are the exact technical data points INVIMA now requires for UDI-DI registration linking? 2. Is your current local representative in Colombia equipped to handle these new digital submission requirements? 3. How does this UDI update affect devices that are already on the market versus new registrations? 4. What are the specific Spanish-language documentation requirements that could trip up your submission? 5. If your product is part of a kit, what is the new compliance burden you urgently need to address? 6. Could this sudden enforcement approach from INVIMA be a sign of future regulatory trends in Peru or Chile? 7. What is the real financial risk of having your products detained at Colombian customs due to non-compliance? --- At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Whether it's managing UDI compliance in Colombia or developing a regulatory strategy for over 30 markets worldwide, we act as your local representative to ensure you maintain market presence. Don't let regulatory surprises disrupt your business. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Pure Global: Chile's MedTech Surprise - Cracking Decree 25's Hidden Regulatory Hurdles.

    Pure Global: Chile's MedTech Surprise - Cracking Decree 25's Hidden Regulatory Hurdles.
    2026/05/06
    This week on LATAM MedTech Insights, we dissect the impactful new regulations quietly introduced in Chile. Exempt Decree No. 25 has significantly expanded the oversight of the national health authority, the ISP, reshaping the compliance landscape for many medical device manufacturers who previously had an easier path to market. We dive into the specifics of what this decree means for your product portfolio, the new registration and surveillance demands you need to be aware of, and the broader implications for the Latin American MedTech market. This is a critical update for anyone operating in or planning to enter Chile. A specific case involves a US-based diagnostics company that saw its projected launch timeline in Chile triple overnight. Their devices, once subject to a simple notification process, are now under the full scope of Decree 25, requiring a comprehensive regulatory submission they were completely unprepared for, jeopardizing their entire regional expansion plan. Key Takeaways: - What is Chile's Exempt Decree No. 25 and which devices does it suddenly affect? - How does this change impact time-to-market and costs for MedTech companies? - Is your current product portfolio compliant with the ISP's newly expanded oversight? - Why is this seemingly small decree a major signal for the entire LATAM region's regulatory future? - What are the three immediate steps you must take to de-risk your Chilean market strategy? - How can you leverage your existing technical documentation for the new requirements? - Could these stricter rules actually create a competitive advantage for well-prepared companies? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.
    続きを読む 一部表示
    2 分
  • Brazil's AI MedTech Firewall: Pure Global on Cracking ANVISA's Surprise Cybersecurity Mandate

    Brazil's AI MedTech Firewall: Pure Global on Cracking ANVISA's Surprise Cybersecurity Mandate
    2026/05/05
    Last week, Brazil's regulatory landscape for MedTech was redefined. ANVISA, the national health agency, unexpectedly rolled out a stringent new framework mandating advanced cybersecurity and data privacy compliance for all AI-driven medical devices. This sudden move disrupts market-entry plans and forces an immediate re-evaluation of regulatory strategies for companies targeting Latin America's largest market. This episode dives deep into the practical consequences of this new regulation. We break down the specific documentation now required, from threat modeling to LGPD compliance, and analyze why simply leveraging your existing FDA or CE Mark approval is no longer a viable path to market access in Brazil. **Key Questions Answered in This Episode:** * What are the specific cybersecurity protocols ANVISA now demands for AI-enabled devices? * How does this new regulation intersect with Brazil's data protection law, the LGPD? * Why is my existing international documentation suddenly insufficient for a Brazilian submission? * What is the single biggest risk for MedTech startups trying to navigate this new rule? * How can this regulatory hurdle be turned into a competitive advantage? * What immediate steps should your company take to de-risk your market entry plan for Brazil? * Are there any "hidden" requirements in the new resolution that could delay your launch? Don't let regulatory hurdles block your access to the vibrant LATAM market. Pure Global combines local expertise with AI-powered data tools to streamline your path to compliance and success. From market access strategy to local representation, we offer end-to-end solutions for MedTech and IVD innovators. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can accelerate your global expansion.
    続きを読む 一部表示
    2 分
adbl_web_anon_alc_button_suppression_c
まだレビューはありません